Trial Profile
A Randomized Phase II Trial Using Dendritic Cells Transduced With an Adenoviral Vector Containing the p53 Gene to Immunize Patients With Extensive Stage Small Cell Lung Cancer in Combination With Chemotherapy With or Without All Trans Retinoic Acid.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs INGN 225 (Primary) ; Paclitaxel; Tretinoin
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 05 Feb 2019 Status changed from active, no longer recruiting to completed.
- 05 Feb 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.